Millennium Management
ALDX icon

Millennium Management’s Aldeyra Therapeutics ALDX Stock Holding History

Millennium Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,600
Closed -$264K – 5971
2025
Q3 		$264K Buy
+50,600
New +$264K ﹤0.01% 5402
2022
Q1 		– Sell
-150,000
Closed -$600K – 6847
2021
Q4 		$600K Buy
+150,000
New +$1.14M ﹤0.01% 4886

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Millennium Management's ALDX Position: Q1 2026 in Review

Millennium Management increased its Aldeyra Therapeutics (ALDX) stake by 2,159% in Q1 2026, buying an estimated $4.17M and bringing the position to 995,243 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #4022.

Millennium Management first reported a position in ALDX in Q2 2015 and has held it in 43 quarters since. The position peaked at $13.1M in Q3 2018. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Millennium Management held 995,243 shares of Aldeyra Therapeutics worth $1.68M as of Q1 2026.
  • Millennium Management bought 951,184 Aldeyra Therapeutics shares in Q1 2026, an estimated $4.17M.
  • Aldeyra Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4022 holding.
  • Millennium Management first reported a position in Aldeyra Therapeutics in Q2 2015 and has held it in 43 quarters since.
  • Millennium Management's Aldeyra Therapeutics position peaked at $13.1M in Q3 2018.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.